TALOS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO TEST THE VASCULAR AND NEUROPROTECTIVE EFFECTS OF CITALOPRAM IN PATIENTS WITH ACUTE ISCHEMIC STROKE
World Stroke Academy. Kraglund K. May 16, 2017; 183379 Disclosure(s): Honoraria from BMS and Pfizer
Kristian Lundsgaard Kraglund
Kristian Lundsgaard Kraglund
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

You may also access WSO content "anytime, anywhere" with the FREE World Stroke Academy App for iOS and Android.
Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies